PR Newswire·Nov 12, 2026, 7:00 AM ET

Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader

Kazia Therapeutics Limited (NASDAQ: KZIA) announced a virtual event on December 2, 2026 at 4:00 PM ET to discuss NDL2.
NDL2 is a novel nuclear PD-L1 protein degrader designed to address immunotherapy resistance in advanced solid tumors.
The company's initial focus for NDL2 is on metastatic breast cancer and colorectal cancer.
NDL2 represents a potentially first-in-class approach within targeted protein degradation, with no known nuclear PD-L1 degraders currently in clinical development.
The virtual event will cover NDL2's scientific discovery, molecular optimization, and pre-IND development.
NDL2 is an optimized bicyclic peptide intended to selectively degrade disease-associated nuclear PD-L1 protein to restore anti-tumor immune responses.
Kazia's lead asset, paxalisib, is an investigational oral dual PI3K/mTOR inhibitor with FDA Fast Track, Orphan Drug, Rare Pediatric Disease, and Orphan Drug designations for various brain tumors.
Kazia is also advancing preclinical programs MSETC (a SETDB1 inhibitor) and EVT801 (a VEGFR-3 inhibitor).
NDL2 remains an investigational, preclinical-stage therapeutic candidate that has not been approved for clinical use.
The press release includes standard forward-looking statements warning of risks related to clinical trial outcomes, regulatory approvals, funding, and intellectual property.